Literature DB >> 23591581

A mathematical analysis of rebound in a target-mediated drug disposition model: I.without feedback.

Philip J Aston1, Gianne Derks, Balaji M Agoram, Piet H van der Graaf.   

Abstract

We consider the possibility of free receptor (antigen/cytokine) levels rebounding to higher than the baseline level after one or more applications of an antibody drug using a target-mediated drug disposition model. Using geometry and dynamical systems analysis, we show that rebound will occur if and only if the elimination rate of the drug-receptor product is slower than the elimination rates of the drug and of the receptor. We also analyse the magnitude of rebound through approximations and simulations and demonstrate that it increases if the drug dose increases or if the difference between the elimination rate of the drug-receptor product and the minimum of the elimination rates of the drug and of the receptor increases.

Mesh:

Year:  2013        PMID: 23591581     DOI: 10.1007/s00285-013-0675-5

Source DB:  PubMed          Journal:  J Math Biol        ISSN: 0303-6812            Impact factor:   2.259


  21 in total

1.  General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  D E Mager; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

2.  Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery.

Authors:  W Cacheux; T Boisserie; L Staudacher; O Vignaux; B Dousset; O Soubrane; B Terris; C Mateus; S Chaussade; F Goldwasser
Journal:  Ann Oncol       Date:  2008-08-05       Impact factor: 32.976

3.  Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers.

Authors:  Chee M Ng; Eric Stefanich; Banmeet S Anand; Paul J Fielder; Louis Vaickus
Journal:  Pharm Res       Date:  2006-11-30       Impact factor: 4.200

Review 4.  Pharmacologic target-mediated drug disposition.

Authors:  G Levy
Journal:  Clin Pharmacol Ther       Date:  1994-09       Impact factor: 6.875

Review 5.  On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach.

Authors:  Guy M L Meno-Tetang; Philip J Lowe
Journal:  Basic Clin Pharmacol Toxicol       Date:  2005-03       Impact factor: 4.080

6.  Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model.

Authors:  Marianne O Stefanini; Florence T H Wu; Feilim Mac Gabhann; Aleksander S Popel
Journal:  Cancer Res       Date:  2010-11-30       Impact factor: 12.701

7.  A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.

Authors:  Jasper J Haringman; Danielle M Gerlag; Tom J M Smeets; Dominique Baeten; Filip van den Bosch; Barry Bresnihan; Ferdinand C Breedveld; Huib J Dinant; Francois Legay; Hermann Gram; Pius Loetscher; Robert Schmouder; Thasia Woodworth; Paul P Tak
Journal:  Arthritis Rheum       Date:  2006-08

8.  Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.

Authors:  Alain Munafo; Anthony Priestley; Ivan Nestorov; Jennifer Visich; Mark Rogge
Journal:  Eur J Clin Pharmacol       Date:  2007-05-01       Impact factor: 2.953

9.  Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics.

Authors:  S Ait-Oudhia; P J Lowe; D E Mager
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26

10.  A mathematical analysis of rebound in a target-mediated drug disposition model: II. With feedback.

Authors:  Philip J Aston; Gianne Derks; Balaji M Agoram; Piet H van der Graaf
Journal:  J Math Biol       Date:  2016-11-10       Impact factor: 2.259

View more
  4 in total

1.  Mathematical analysis and drug exposure evaluation of pharmacokinetic models with endogenous production and simultaneous first-order and Michaelis-Menten elimination: the case of single dose.

Authors:  Xiaotian Wu; Fahima Nekka; Jun Li
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-07-09       Impact factor: 2.745

2.  Investigating receptor enzyme activity using time-scale analysis.

Authors:  Tao You; Hong Yue
Journal:  IET Syst Biol       Date:  2015-12       Impact factor: 1.615

3.  A mathematical analysis of rebound in a target-mediated drug disposition model: II. With feedback.

Authors:  Philip J Aston; Gianne Derks; Balaji M Agoram; Piet H van der Graaf
Journal:  J Math Biol       Date:  2016-11-10       Impact factor: 2.259

4.  A Tutorial on Target-Mediated Drug Disposition (TMDD) Models.

Authors:  P Dua; E Hawkins; P H van der Graaf
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-06-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.